Cholestatic Hepatitis and Suppressed Gonadotropins in a Bodybuilder Using Internet Supplements
A 26-year-old male bodybuilder presents with 10 days of jaundice, pruritus, dark urine, and right upper quadrant discomfort. He denies alcohol, injection drug use, and acetaminophen overuse. For 8 weeks he has taken a 'legal' oral muscle-building supplement purchased online and, for the past 4 weeks, tamoxifen 20 mg daily obtained from a gym contact to prevent gynecomastia. He also used intramuscular testosterone 400 mg weekly for 6 weeks, stopping 5 weeks ago. Examination: temp 37.1°C, BP 128/78, scleral icterus, no stigmata of chronic liver disease. Labs: total bilirubin 8.2 mg/dL (direct 5.9), ALP 410 U/L, ALT 220 U/L, AST 180 U/L, INR 1.4, albumin 3.6, platelets 210,000. Total testosterone 120 ng/dL (ref 300–1000), LH 0.4 IU/L, FSH 0.6 IU/L. Hepatitis B and C serologies and HIV are negative; acetaminophen undetectable. Right upper quadrant ultrasound shows no biliary dilation.
1. Which injury pattern does the biochemical profile suggest, and how do the hormone values change your interpretation?
Read the worked answer
The pattern is mixed cholestatic-hepatocellular injury: the ALP is markedly elevated, the bilirubin is high with a direct predominance, and the transaminases are only moderately increased. In a bodybuilder using an oral 'supplement,' this pattern should raise suspicion for an anabolic-androgenic steroid or an adulterant in the product; oral C17-alkylated steroids are classically associated with cholestatic hepatitis. Tamoxifen can also cause hepatic injury, but it more often produces steatosis or steatohepatitis, and it does not explain the hormone profile.
The low total testosterone with low LH and FSH indicates secondary hypogonadism from exogenous androgen exposure, not primary testicular failure. The suppressed gonadotropins are the key clue that the patient's own axis is shut down. That matters because recovery may take weeks to months and because the patient may try to self-treat with tamoxifen or human chorionic gonadotropin. The immediate priority is to stop all hormonal and supplement products and to monitor synthetic function and mental status.
2. What immediate management and reporting steps are indicated?
Read the worked answer
Stop the supplement, testosterone, and tamoxifen. Provide supportive care, avoid additional hepatotoxins, and monitor INR, bilirubin, transaminases, and mental status. Viral and autoimmune causes have not been fully excluded; check autoimmune markers and review vaccination and travel history, and obtain a hepatology consultation if the INR rises or encephalopathy develops. Ultrasound has excluded large-duct obstruction.
There is no routine role for corticosteroids in supplement-associated cholestatic hepatitis. If injury persists after discontinuation, liver biopsy may help distinguish drug-induced injury from other causes. Report the product to the FDA MedWatch program and, where required, the state health department; the supplement may contain an undeclared steroid or adulterant. Counsel the patient that 'legal' does not mean safe and that resuming the product could reproduce the injury.
3. What endocrine and behavioral issues should be anticipated after discharge?
Read the worked answer
After stopping exogenous androgen, the hypothalamic-pituitary-gonadal axis may remain suppressed for weeks to months. Expect fatigue, low libido, depressed mood, and possible relapse to steroid use. Check morning testosterone and gonadotropins periodically rather than treating immediately with more androgen. Refer for endocrine follow-up and for substance use or body-image counseling.
Anabolic-androgenic steroid use can meet criteria for a substance use disorder, and withdrawal is more psychological than autonomic. Screen for depression and suicidality, and address gym culture and peer supply. Education should include the risks of contaminated products, hepatic injury, cardiomyopathy, and hypogonadism. A written plan with clear follow-up is more useful than a single warning.